GLS and cancer: The steroid-activated androgen receptor (AR) can also decrease the c-MYC signaling pathway, which accounts for driving reinforced glutaminolysis in cancer cells through regulating glutamine transporters and GLS1 directly or indirectly (via miRNA) [74,92,93].